Silence Therapeutics Reports Q3 2026 Results, $247.7M Cash Position

Silence Therapeutics reported a third-quarter 2026 net loss of $12.4 million, or $0.08 per share, compared with a $21.0 million loss a year earlier. Revenue was zero, and cash and cash equivalents totaled $247.7 million at quarter-end. The company also highlighted positive Phase 2 results for dives…